☰

Ping-Chiao Tsai, Ph.D. - Publications

Affiliations: 
2012 Roswell Park . Microbiology and Immunology State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Oncology, Molecular Biology, Immunology
Tree Info Similar researchers PubMed Report error

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Liu Y, Gu JJ, Yang L, Tsai PC, Guo Y, Xue K, Xia Z, Liu X, Lv F, Cao J, Hong X, Mavis C, Hernandez-Ilizaliturri FJ, Zhang Q. The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance. Aging. 12. PMID 33288735 DOI: 10.18632/aging.202180  0.421
2012 Huang WT, Weng SW, Huang CC, Lin HC, Tsai PC, Chuang JH. Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFκB pathway. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 120: 872-81. PMID 23009111 DOI: 10.1111/j.1600-0463.2012.02915.x  0.304
2012 Chou MH, Chuang JH, Eng HL, Tsai PC, Hsieh CS, Liu HC, Wang CH, Lin CY, Lin TM. Effects of hepatocyte CD14 upregulation during cholestasis on endotoxin sensitivity. Plos One. 7: e34903. PMID 22511970 DOI: 10.1371/journal.pone.0034903  0.342
2012 Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1039-50. PMID 22228637 DOI: 10.1158/1078-0432.Ccr-11-1429  0.632
2012 Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology. 156: 490-8. PMID 22150234 DOI: 10.1111/J.1365-2141.2011.08966.X  0.651
2012 Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri F. Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. Blood. 120: 2757-2757. DOI: 10.1182/Blood.V120.21.2757.2757  0.66
2012 Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri F, Czuczman MS. Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models. Blood. 120: 2756-2756. DOI: 10.1182/Blood.V120.21.2756.2756  0.645
2011 Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 153: 599-611. PMID 21492126 DOI: 10.1111/J.1365-2141.2011.08669.X  0.567
2010 Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. Journal of Clinical Oncology. 28: 8095-8095. DOI: 10.1200/Jco.2010.28.15_Suppl.8095  0.634
2010 Riaz W, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Czuczman MS. Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). Journal of Clinical Oncology. 28: 8094-8094. DOI: 10.1200/Jco.2010.28.15_Suppl.8094  0.512
2010 Tsai P, Dvorak P, Bangia N, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. Rituximab Resistance Is Associated with Global Downregulation of CD20 and CD54 In B-Cell Lymphoma Cells: Implication of CD20 Signaling on CD54 Blood. 116: 5077-5077. DOI: 10.1182/Blood.V116.21.5077.5077  0.656
2010 Barth M, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs J, Deeb G, Czuczman MS. Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL) Blood. 116: 3917-3917. DOI: 10.1182/Blood.V116.21.3917.3917  0.67
2008 Tsai P, Bangia N, Olejniczak S, Hernandez-Ilizaliturri FJ, Czuczman M. The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity Blood. 112: 2607-2607. DOI: 10.1182/Blood.V112.11.2607.2607  0.669
2007 Tsai P, Hernandez-Ilizaliturri FJ, Olejniczak SH, Naveen B, Czuczman MS. Modulation of CD20 Expression in Rituximab-Sensitive (RSCL) and Rituximab Resistant Cell Lines (RRCL) Using IL-4 and Bryostatin-1. Blood. 110: 2619-2619. DOI: 10.1182/Blood.V110.11.2619.2619  0.611
Show low-probability matches.